Clinical trials are currently exploring LA-GIPR agonists (Muller et al. 2022) to determine their effects on body weight loss, T2DM, and energy metabolism, and whether GIP actions are dependent or independent of insulin levels and/or insulin sensitivity. This evidence concerns the gene INS and type 2 diabetes mellitus.